[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100136334":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":36,"centralContacts":11,"locations":40,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":11,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13,14,15,16],"Drug: RO4917523","Drug: escitalopram","Drug: methylphenidate","Drug: placebo",[18,23,28,33],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","RO4917523","Oral single dose",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":26},"escitalopram",[9],[27],"Lexapro",{"type":19,"name":29,"description":21,"armGroupLabels":30,"otherNames":31},"methylphenidate",[9],[32],"Ritalin",{"type":19,"name":34,"description":21,"armGroupLabels":35,"otherNames":11},"placebo",[9],[37],{"name":38,"affiliation":5,"role":39},"Clinical Trials","STUDY_DIRECTOR",[41],{"facility":11,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":11},"La Jolla","California","92093","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.2742,32.84727,{"lat":51,"lon":50},{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100136334","phase-1-a-study-of-the-ability-of-functional-magnetic-resonance-imaging-fmri-to-detect-and-characterize-the-effects-of-two-marketed-centrally-active-drugs-placebo-and-ro4917523-in-healthy-volunteers-100136334",false,"NCT01045083","A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers","Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro]), a Dopamine","Inclusion Criteria:\n\n* Adult patients, 18 to 45 years of age\n* In good general health\n* Weight of \\≥120 lbs (55 kg) and a body mass index (BMI) between 18 to 30kg\u002Fm²\n* Males and females with reproductive potential: willing to use a reliable method of contraception\n\nExclusion Criteria:\n\n* Evidence of clinically significant disease\n* Medical or surgical condition that could alter the absorption, metabolism, or elimination of drugs\n* Family history of sudden death or ventricular arrhythmia\n* History of any psychiatric disorder and\u002For marked anxiety\n* History of glaucoma\n* History (including family) of motor tic or diagnosis of Tourette's syndrome\n* Active suicide ideation\n* Contraindication to MRI",true,"ALL","18 Years","45 Years",{"count":67,"type":68},25,"ACTUAL","INTERVENTIONAL",[71],"PHASE1","This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.",[74],"Healthy Volunteer","COMPLETED","2016-11-01",{"date":78,"type":79},"2016-11-02","ESTIMATED",{"date":81,"type":11},"2010-01",{"date":83,"type":68},"2011-06",{"name":5,"class":6},1]